Ubs Oconnor LLC Iovance Biotherapeutics, Inc. Call Options Transaction History

Ubs Oconnor LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$7.59 - $17.47 $2.2 Million - $5.07 Million	-290,000 Reduced 87.88%	40,000 $592,000
Q4 2023 Feb 14, 2024	BUY	$3.3 - $8.89 $330,000 - $889,000	100,000 Added 43.48%	330,000 $2.68 Million
Q3 2023 Nov 14, 2023	BUY	$4.44 - $8.79 $1.02 Million - $2.02 Million	230,000 New	230,000 $1.05 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $553,000 - $822,000	100,000 New	100,000 $611,000

319

239M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $945M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.